# NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

> **NCT06239272** · PHASE1,PHASE2 · RECRUITING · sponsor: **St. Jude Children's Research Hospital** · enrollment: 139 (estimated)

## Conditions studied

- Adipocytic Neoplasm
- Liposarcoma
- Atypical Fibroxanthoma
- Angiomatoid Fibrous Histiocytoma
- Myoepithelioma
- Fibrosarcoma NOS
- Myxofibrosarcoma
- Angiosarcoma
- Osteosarcoma, Extraskeletal

## Interventions

- **PROCEDURE:** Surgical resection
- **RADIATION:** Proton beam radiation therapy
- **DRUG:** Pazopanib
- **DRUG:** Ifosfamide
- **DRUG:** Doxorubicin
- **DRUG:** Selinexor

## Key facts

- **NCT ID:** NCT06239272
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-27
- **Primary completion:** 2034-06
- **Final completion:** 2037-06
- **Target enrollment:** 139 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06239272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06239272, "NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06239272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*